Role of a Disease-associated ST3Gal-4 in Non-small Cell Lung Cancer

Praveen Singh1, Archana Joon1, Munmun Kumari1

  • 1Department of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012, India.

Insights

ST3Gal-4, a sialyltransferase, is upregulated in non-small cell lung cancer (NSCLC). Silencing ST3Gal-4 reduces NSCLC cell proliferation, invasion, and migration by affecting key signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Sialylation is crucial for cancer progression, influencing apoptosis, growth, invasion, and metastasis.
  • Aberrant expression of sialyltransferases synthesizes tumor-associated sialylated structures.
  • ST3Gal-4 transcript is significantly upregulated in major non-small cell lung cancer (NSCLC) subtypes.

Purpose of the Study:

  • To investigate the role of ST3Gal-4 in NSCLC proliferation, invasion, and migration.
  • To elucidate the impact of ST3Gal-4 on cancer-associated signal transduction pathways in NSCLC cells.

Main Methods:

  • Silencing of ST3Gal-4 using esi-ST3Gal-4-RNA in NSCLC cell lines (NCI-H520 and A549).
  • Confirmation of ST3Gal-4 silencing via RT-PCR and western immunoblotting.
  • Assessment of downstream signaling molecules including MAL-I interacting membrane-HSP60, β-catenin, E-cadherin, AKT1, ERK1/2, and NF-ƙB.

Main Results:

  • ST3Gal-4 silencing significantly reduced proliferation, invasion, and migration in both NSCLC cell lines.
  • Downregulation of MAL-I interacting membrane-HSP60, a potential α2,3-sialylated glycoprotein, was observed upon ST3Gal-4 silencing.
  • Reduced expression of activated AKT1, ERK1/2, NF-ƙB, and altered E-cadherin/β-catenin signaling pathways were noted.

Conclusions:

  • ST3Gal-4 plays a critical role in NSCLC progression by mediating α2,3 sialylation of membrane proteins like HSP60.
  • ST3Gal-4 influences protein conformation, activating signaling pathways essential for NSCLC proliferation, invasion, and migration.
  • ST3Gal-4 represents a potential therapeutic target for NSCLC treatment.